ATE308342T1 - Arzneimittel gegen diabetes-komplikationen - Google Patents

Arzneimittel gegen diabetes-komplikationen

Info

Publication number
ATE308342T1
ATE308342T1 AT98936696T AT98936696T ATE308342T1 AT E308342 T1 ATE308342 T1 AT E308342T1 AT 98936696 T AT98936696 T AT 98936696T AT 98936696 T AT98936696 T AT 98936696T AT E308342 T1 ATE308342 T1 AT E308342T1
Authority
AT
Austria
Prior art keywords
drugs
ameliorating
diabetes
efficacious
treating
Prior art date
Application number
AT98936696T
Other languages
English (en)
Inventor
Hiroshi Chugai Koga
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE308342T1 publication Critical patent/ATE308342T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98936696T 1997-08-08 1998-08-07 Arzneimittel gegen diabetes-komplikationen ATE308342T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21465997 1997-08-08
PCT/JP1998/003525 WO1999007411A1 (fr) 1997-08-08 1998-08-07 Remedes contre les complications du diabete

Publications (1)

Publication Number Publication Date
ATE308342T1 true ATE308342T1 (de) 2005-11-15

Family

ID=16659441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936696T ATE308342T1 (de) 1997-08-08 1998-08-07 Arzneimittel gegen diabetes-komplikationen

Country Status (7)

Country Link
US (1) US6218411B1 (de)
EP (1) EP1004316B1 (de)
AT (1) ATE308342T1 (de)
AU (1) AU8561298A (de)
DE (1) DE69832176T2 (de)
ES (1) ES2251095T3 (de)
WO (1) WO1999007411A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
TW200626163A (en) * 2004-09-22 2006-08-01 Kureha Corp Agent for treating or preventing diabetic neuropathy
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US20110257202A1 (en) * 2008-10-19 2011-10-20 Richard J Johnson Therapeutic Compositions and Methods for Treating Chronic Kidney Disease Associated with a Metabolic Imbalance
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
KR20220098746A (ko) 2019-11-08 2022-07-12 제논 파마슈티칼스 인크. 우울 장애 치료 방법
CN113730581A (zh) * 2020-05-28 2021-12-03 杭州起岸生物科技有限公司 钾atp通道调节剂在制备抗糖尿病肾病药物中的应用
IL304920A (en) 2021-02-09 2023-10-01 Xenon Pharmaceuticals Inc A voltage-gated potassium channel opener for use in the treatment of anhedonia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940000232B1 (ko) * 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
WO1989010757A1 (en) * 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
TW224941B (de) * 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
CA2061179A1 (en) * 1991-02-18 1992-08-19 Ryuji Tsuzuki Oxzazinobenzazole compounds
ZA93436B (en) * 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
JPH08175994A (ja) * 1994-10-27 1996-07-09 Takeda Chem Ind Ltd 脂質代謝改善剤
CA2159851A1 (en) * 1994-11-07 1996-05-08 Gary J. Grover Combination of a potassium channel activator and a biguanide non-sulfonylurea agent
WO1998029135A1 (fr) * 1996-12-26 1998-07-09 Kirin Beer Kabushiki Kaisha Medicaments pour soigner les troubles de la circulation ophtalmiques

Also Published As

Publication number Publication date
EP1004316A4 (de) 2003-02-12
DE69832176T2 (de) 2006-08-03
WO1999007411A1 (fr) 1999-02-18
ES2251095T3 (es) 2006-04-16
AU8561298A (en) 1999-03-01
US6218411B1 (en) 2001-04-17
DE69832176D1 (de) 2005-12-08
EP1004316B1 (de) 2005-11-02
EP1004316A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
ATE308342T1 (de) Arzneimittel gegen diabetes-komplikationen
FR2728793B1 (de)
EP0766960A4 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
BR9509853A (pt) Formulação farmacêutica uso da mesma e processos para fabricar a mesma para tratar um paciente em necessidade de tratamento anti-trombótico para tratar tromboembolismo e para intensificar a absorção do composto terapeuticamente ativo
DE69424546D1 (de) Thermoplastische elastomere copolymere und diese enthaltendes haar- und hautpflegemittel
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
MY117526A (en) N-(3-benzofuranyl)urea-derivatives
AU3459689A (en) Treatment of skin disorders
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
ATE212829T1 (de) Feste, wasserfreie, pharmazeutische zubereitungen für vaginale verwendung
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
BG101126A (en) The use of muramylpeptide compounds
DE69626401D1 (de) Arzneimittel zur topischen anwendung
EP0750912A3 (de) Batroxobin enthaltende Arzneimittel zur Behandlung und Prophylaxe von ischämischen Reperfusionsschäden
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
AU7655494A (en) Treatment of laminitis
WO2003082283A3 (en) Pharmaceutical composition with combined active agents and methods for using the same
KR900701322A (ko) 포도필린과 재조합 DNA인간 α인터페론의 배합물로 생식기 우췌를 치료하는 방법
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
ATE147983T1 (de) Transdermales therapeutisches system mit pentylentetrazol als wirkstoff
KR950007852A (ko) 우라실을 유효성분으로 함유하는 관절염 치료제
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
UA39988C2 (uk) Антимікробний засіб" асперсепт" та спосіб лікування та профілактики інфекційних уражень шкіри за допомогою цього засобу

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties